NCT02361944View on ClinicalTrials.gov

Risk of Oxygen During Cardiac Surgery Trial

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

April 5, 2016

Primary Completion Date

October 8, 2020

Study Completion Date

January 8, 2021

Conditions
Cardiac Surgery
Interventions
DRUG

Oxygen - normoxia

Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)

DRUG

Oxygen - hyperoxia

Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass

Trial Locations (1)

37212

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
collaborator

National Institute of General Medical Sciences (NIGMS)

NIH

lead

Vanderbilt University

OTHER

NCT02361944 - Risk of Oxygen During Cardiac Surgery Trial | Biotech Hunter | Biotech Hunter